Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 8Esophageal Squamous Cell Carcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Rectal Neoplasms 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Esophageal Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Rectal Diseases 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Intestinal Diseases 1Digestive System Diseases 1Colonic Diseases 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × Levoleucovorin × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡